<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098692</url>
  </required_header>
  <id_info>
    <org_study_id>DZB-CS-102</org_study_id>
    <nct_id>NCT04098692</nct_id>
  </id_info>
  <brief_title>Mass Balance and Pharmacokinetics Study of Derazantinib in Healthy Male Subjects</brief_title>
  <official_title>A Phase 1, Two-part, Open-label, Single-oral-dose Study to Investigate the Absolute Bioavailability and Absorption, Pharmacokinetics, Distribution, Metabolism, and Excretion of [14C]-Derazantinib in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basilea Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basilea Pharmaceutica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, two-part, open-label, single centre, single arm study in healthy male
      subjects to investigate the oral PK, intravenous (IV) PK, mass balance, bioavailability and
      metabolites profiling and identification of derazantinib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Actual">November 18, 2019</completion_date>
  <primary_completion_date type="Actual">November 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the PK of total radioactivity, [14C]-derazantinib, derazantinib, and BAL0122840: Cmax</measure>
    <time_frame>up to Day 50</time_frame>
    <description>Assessment of the maximum observed plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the PK of total radioactivity, [14C]-derazantinib, derazantinib, and BAL0122840: Tmax</measure>
    <time_frame>up to Day 50</time_frame>
    <description>Assessment of the time from dosing at which Cmax was apparent (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the PK of total radioactivity, [14C]-derazantinib, derazantinib, and BAL0122840: t½</measure>
    <time_frame>up to Day 50</time_frame>
    <description>Assessment of the apparent terminal elimination half-life (t½)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the PK of total radioactivity, [14C]-derazantinib, derazantinib, and BAL0122840: AUC0-t</measure>
    <time_frame>up to Day 50</time_frame>
    <description>Assessment of the area under the concentration-time curve from dosing to the last measurable concentration (AUC0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the PK of total radioactivity, [14C]-derazantinib, derazantinib, and BAL0122840: AUC0-inf</measure>
    <time_frame>up to Day 50</time_frame>
    <description>Assessment of the area under the concentration-time curve from dosing extrapolated to infinity (AUC0-inf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the PK of total radioactivity, [14C]-derazantinib, derazantinib, and BAL0122840: Tlast</measure>
    <time_frame>up to Day 50</time_frame>
    <description>Assessment of the time of the last measurable (positive) concentration (Tlast)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the PK of [14C]-derazantinib: CL</measure>
    <time_frame>up to Day 50</time_frame>
    <description>Assessment of the total clearance (CL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the PK of [14C]-derazantinib: Vss</measure>
    <time_frame>up to Day 50</time_frame>
    <description>Assessment of the volume of distribution at steady state (Vss)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the PK of [14C]-derazantinib: Vd</measure>
    <time_frame>up to Day 50</time_frame>
    <description>Assessment of the volume of distribution (Vd)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the PK of derazantinib: CL/F</measure>
    <time_frame>up to Day 50</time_frame>
    <description>Apparent total clearance (CL/F)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the PK of derazantinib: F</measure>
    <time_frame>up to Day 50</time_frame>
    <description>Absolute bioavailability (F)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the rate and routes of excretion, and the mass balance of total radioactivity in urine and faeces and in all excreta</measure>
    <time_frame>up to Day 50</time_frame>
    <description>Assessment of total radioactivity by measuring the amount excreted (Ae), Ae as a percentage of the administered dose (%Ae), cumulative recovery (CumAe), and cumulative recovery expressed as a percentage of the dose (Cum%Ae)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Single-Arm: Derazantinib (Part 1 and Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: 300 mg Derazantinib oral administration followed by 100 μg [14C]-Derazantinib intravenous microdose
Part 2: 300 mg [14C]-Derazantinib oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Derazantinib capsule</intervention_name>
    <description>300 mg derazantinib oral administration (3x100 mg capsules)</description>
    <arm_group_label>Single-Arm: Derazantinib (Part 1 and Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-Derazantinib solution for infusion</intervention_name>
    <description>100 μg [14C]-derazantinib intravenous administration</description>
    <arm_group_label>Single-Arm: Derazantinib (Part 1 and Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-Derazantinib capsule</intervention_name>
    <description>300 mg [14C]-derazantinib oral administration (3x100 mg capsules)</description>
    <arm_group_label>Single-Arm: Derazantinib (Part 1 and Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males

          -  Age 18 to ≤ 55 years (Part 1)

          -  Age 30 to ≤ 65 years (Part 2)

          -  Body mass index of 18.0 to 29.0 kg/m² and a minimum body weight of 50 kg

          -  Must have regular bowel movements

          -  Must agree to adhere to the contraception requirements

        Exclusion Criteria:

          -  Male subjects with pregnant partners

          -  Subjects who have received any investigational medicine in a clinical research study
             within the previous 3 months

          -  Subjects who are study site employees, or immediate family members of a study site or
             sponsor employee

          -  History of any drug or alcohol abuse in the 12 months prior to dosing

          -  Regular alcohol consumption in males &gt; 21 units per week

          -  Smokers and users of e-cigarettes and nicotine replacement products and those who have
             used these products within the last 3 months

          -  Radiation exposure (diagnostic x-rays and other medical exposures, exceeding 5 mSv in
             the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as
             defined in the Ionising Radiation Regulations 2017, shall participate in the study

          -  Participation in any study involving administration of any [14C]-labelled compound
             within 12 months prior to screening (Part 1 only)

          -  Excessive caffeine consumption within 14 days prior to screening, defined as 800 mg
             per day (approximately 6 large cups of coffee)

          -  Subjects who do not have suitable veins

          -  Clinically significant abnormal biochemistry, haematology or urinalysis as judged by
             the Investigator

          -  Confirmed positive drugs of abuse test result

          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or
             human immunodeficiency virus (HIV) results, or history of immunodeficiency diseases,
             including a positive HIV (ELISA and western blot) test result

          -  Evidence of renal impairment at screening, as indicated by an estimated creatinine
             clearance of &lt; 70 mL/min using the Cockcroft-Gault equation

          -  History of clinically significant cardiovascular, renal, hepatic, chronic respiratory
             or gastrointestinal disease, neurological or psychiatric disorder or current clinical
             evidence of any corneal or retinal disorder

          -  Presence or history of clinically significant allergy requiring treatment, as judged
             by the investigator. Hay fever is allowed unless it is active

          -  Known hypersensitivity or allergy to natural rubber latex

          -  History of any food allergies

          -  History of clinically significant ECG abnormalities

          -  Familial history of sick-sinus syndrome

          -  Recent (within the last 3 years) and/or recurrent history of autonomic dysfunction

          -  Recent (within the last 3 years) and/or recurrent history of acute or chronic
             bronchospastic disease (including asthma disease, treated or not treated)

          -  History of malignancy of any organ system (other than localised basal cell carcinoma
             of the skin), treated or untreated, within the past 5 years

          -  Use of any prescription drugs (including vaccines), herbal supplements (such as St.
             John's Wort, homeopathic preparations), within 4 weeks prior to initial dosing, and/or
             over-the-counter medication, dietary supplements (vitamins and minerals included)
             within 2 weeks prior to initial dosing

          -  Donation or loss of 400 mL or more of blood and/or plasma within 3 months prior to
             initial dosing

          -  Any history or presence of frequent episodes of diarrhoea (defined as an increase of 4
             to 6 stools per day over usual individual defecation pattern).

          -  Significant illness within 2 weeks prior to initial dosing

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism, or excretion of drugs, or which may jeopardise the subject
             in case of participation in the study.

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nand Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences, Ruddington</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

